Gossamer Bio Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(56,528) | $(179,817) | $(229,378) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 833 | 1,607 | 1,832 |
| Stock-based compensation expense | 20,619 | 28,518 | 42,553 |
| In process research and development expenses | — | 10,000 | 65 |
| Amortization of operating lease right-of-use assets | 3,318 | 2,778 | 2,597 |
| Amortization of long-term debt discount and issuance costs | 1,086 | 1,321 | 1,163 |
| Amortization of premium on investments, net of accretion of discounts | (13,062) | (9,450) | (1,405) |
| Loss on disposal of property and equipment | 806 | 726 | — |
| Changes in operating assets and liabilities: | |||
| Receivable from contracts with collaborators | (5,338) | — | — |
| Prepaid expenses and other current assets | 62 | (3,892) | 296 |
| Other assets | 335 | 62 | 400 |
| Operating lease liabilities | (3,386) | (2,982) | (2,721) |
| Accounts payable | (1,656) | 3,990 | (1,813) |
| Accrued expenses | (10,718) | (835) | (1,659) |
| Accrued research and development expenses | 2,676 | (7,847) | (579) |
| Accrued compensation and benefits | 1,701 | (3,240) | 1,618 |
| Contract liabilities | 55,919 | — | — |
| Accrued interest expense | (135) | (97) | (1) |
| Net cash used in operating activities | (3,468) | (159,158) | (187,032) |
| Cash flows from investing activities | |||
| Research and development asset acquisitions, net of cash acquired | — | — | (65) |
| Purchase of marketable securities | (494,777) | (441,670) | (238,060) |
| Maturities of marketable securities | 523,800 | 330,700 | 237,500 |
| Purchase of property and equipment | — | — | (410) |
| Net cash provided by (used in) investing activities | 29,023 | (110,970) | (1,035) |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock and warrants in a private offering, net of offering costs | — | 201,323 | 119,946 |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 629 | 444 | 1,214 |
| Proceeds from the exercise of stock options | — | — | 1,736 |
| Proceeds from issuance of equity option pursuant to stock purchase agreement | 464 | — | — |
| Principal repayments of long-term debt | (12,581) | (11,613) | (5,806) |
| Net cash provided by (used in) financing activities | (11,488) | 190,154 | 117,090 |
| Effect of exchange rate changes on cash and cash equivalents | (102) | 110 | (517) |
| Net increase (decrease) in cash and cash equivalents | 13,965 | (79,864) | (71,494) |
| Cash and cash equivalents, at the beginning of the period | 32,109 | 111,973 | 183,467 |
| Cash and cash equivalents, at the end of the period | $46,074 | $32,109 | $111,973 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $10,561 | $12,288 | $12,712 |
| Supplemental disclosure of noncash investing and financing activities: | |||
| Right-of-use assets obtained in exchange for lease liabilities | $5,298 | $— | $3,029 |
| Change in unrealized gain (loss) on marketable securities, net | $89 | $191 | $(75) |
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $— | $— | $83 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.